490 ARSENAL WAY, SUITE 200, WATERTOWN, MA
Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Earnings Release
Shareholder votes
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports First Quarter 2025 Financial Results and Provides Business Update
Amended material disclosure
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
SEC Staff Correspondence